Adaptive Biotechnologies Corporation

XNASHealth care

Last traded price · USD

$26.86

+0.55%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 14:44 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $26.71
Volume: 5
Day's high: —
Day's low: —

In brief

Adaptive Biotechnologies Corporation is a health care company listed on Nasdaq, valued at about $4.29B.
Its shares closed at $26.71 on 4 Nov 2026, up 57.9% over the past year.
From India you can buy ADPT in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Adaptive Biotechnologies Corporation (ADPT) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole ADPT share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade ADPT options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Ahead of SPY and its sector fund XLV over 1 year
1 month: −0.7% (SPY −1.6%, XLV +13.5%). 3 months: +8.6% (SPY −0.4%, XLV +15.5%). 1 year: +57.9% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: ADPT, SPY and XLV · as of 4 Nov 2026
5.0 days to cover short interest
12.0M shares were sold short at the 15 Oct 2026 settlement, 7.5% of the 159.6M shares outstanding; covering them would take 5.0 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Above its 50- and 200-day averages
The 4 Nov 2026 close of $26.71 was 1.3% above its 50-day average ($26.37) and 35.4% above its 200-day average ($19.73). It has closed above the 200-day for 108 sessions, since 3 Jun 2026. The 50-day average crossed above the 200-day on 1 Jul 2026, 88 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
78% of the way up its 52-week range
Closed at $26.71 on 4 Nov 2026: 13.1% below the 52-week high of $30.74 (6 Oct 2026) and 122.6% above the low of $12.00 (12 Mar 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−0.7%

6 months+85.1%

1 year+57.9%

5 years−27.5%

Newswire

About

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

Website

Notable moves

May 2, 2025
+33.70%
September 26, 2024
+22.50%
November 10, 2022
+24.97%

Newswire

About

Website

Notable moves

May 2, 2025
+33.70%
September 26, 2024
+22.50%
November 10, 2022
+24.97%

Adaptive Biotechnologies Corporation

XNASHealth care

Last traded price · USD

$26.86

+0.55%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 14:44 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $26.71
Volume: 5
Day's high: —
Day's low: —

In brief

Adaptive Biotechnologies Corporation is a health care company listed on Nasdaq, valued at about $4.29B.
Its shares closed at $26.71 on 4 Nov 2026, up 57.9% over the past year.
From India you can buy ADPT in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Adaptive Biotechnologies Corporation (ADPT) shares from India?

Do I need the price of a whole ADPT share to invest?

How much can I invest in US stocks in a year?

Can I trade ADPT options or futures?

Insights

Quotes run fifteen minutes behind.

Ahead of SPY and its sector fund XLV over 1 year
1 month: −0.7% (SPY −1.6%, XLV +13.5%). 3 months: +8.6% (SPY −0.4%, XLV +15.5%). 1 year: +57.9% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: ADPT, SPY and XLV · as of 4 Nov 2026
5.0 days to cover short interest
12.0M shares were sold short at the 15 Oct 2026 settlement, 7.5% of the 159.6M shares outstanding; covering them would take 5.0 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Above its 50- and 200-day averages
The 4 Nov 2026 close of $26.71 was 1.3% above its 50-day average ($26.37) and 35.4% above its 200-day average ($19.73). It has closed above the 200-day for 108 sessions, since 3 Jun 2026. The 50-day average crossed above the 200-day on 1 Jul 2026, 88 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
78% of the way up its 52-week range
Closed at $26.71 on 4 Nov 2026: 13.1% below the 52-week high of $30.74 (6 Oct 2026) and 122.6% above the low of $12.00 (12 Mar 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−0.7%

6 months+85.1%

1 year+57.9%

5 years−27.5%

Newswire

About

Website

Notable moves

May 2, 2025
+33.70%
September 26, 2024
+22.50%
November 10, 2022
+24.97%

Newswire

About

Website

Notable moves

May 2, 2025
+33.70%
September 26, 2024
+22.50%
November 10, 2022
+24.97%

Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corporation in brief

Ahead of SPY and its sector fund XLV over 1 year

5.0 days to cover short interest

Above its 50- and 200-day averages

78% of the way up its 52-week range

Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corporation in brief

Ahead of SPY and its sector fund XLV over 1 year

5.0 days to cover short interest

Above its 50- and 200-day averages

78% of the way up its 52-week range